Gapping up
In reaction to earnings/guidance:
- BBW +1.8% (reaffirms guidance in presentation)
Other news:
- AZRX +11.2% (CEO issues letter to shareholders regarding recent acquisition of First Wave Bio and creation of First Wave BioPharma)
- AXSM +8% (FDA accepts NDA for migraine treatment AXS-07; PDUFA date set for April 30, 2022)
- KERN +7.9% (to acquire 365 Cannabis in a $17 mln deal)
- ZLAB +7.7% (receives Breakthrough Therapy Designation for Bemarituzumab in China)
- PNT +6.1% (POINT Biopharma and Convergent Therapeutics announce collaboration to evaluate CONV 01-a (Rosopatamab-225Ac) in combination with PNT2002)
- NRXP +6% (IQV to collaborate with NRXP on potential medical support for novel COVID-19 treatment)
- AVNT +4.6% (expects double-digit revenue in its composite solutions)
- SPIR +4.1% (to acquire exactEarth (EXRTF) for approx. $161.2 mln in cash and stock; to be accretive to revs, adj. EBITDA)
- ANGI +3.6% (report monthly metrics for August)
- ARAY +3.5% (reports CyberKnife Robotic Radiotherapy Platform is superior to conventional linear accelerators)
- QTRX +3.3% (FDA expands EUA label for its Simoa SARS-CoV-2 N Protein Antigen Test)
- GLDD +3% (announces receipt of several major dredging awards totaling $261.3 mln)
- VCTR +2.3% (reports August AUM)
- INCY +1.1% (Ruxolitinib Cream data accepted for presentation at EADV)
- NVCR +1.1% (has entered into a clinical trial collaboration agreement with Roche (RHHBY))
- MNR +1% (reinitiates exploration of strategic alternatives)
- RWT +1% (increases dividend)
- SENS +1% (announces collaboration with the University Hospitals)
Analyst comments:
- JNCE +4.6% (upgraded to Outperform from Mkt Perform at Raymond James)
- DXC +1.9% (upgraded to Buy from Neutral at BofA Securities)
- LESL +1.3% (upgraded to Buy from Hold at Berenberg)
- KLAC +0.9% (upgraded to Positive from Neutral at Susquehanna)